DEFA14A: Entera Bio Schedules Annual Shareholder Meeting to Vote on Director Election and Executive Compensation

Entera Bio Ltd. has announced its upcoming Annual Shareholder Meeting on July 16, 2025, where shareholders will vote on the election of a Class II director, ratification of executive compensation, and the appointment of independent auditors.

Summary

• Entera Bio Ltd. will hold its Annual Shareholder Meeting on Wednesday, July 16, 2025, at 8:00 AM Eastern Time in Jerusalem, Israel.
• Shareholders are invited to vote on seven key proposals, with proxy materials available online.
• Proposal 1 involves the election of Ms. Haya Taitel as a Class II member of the Board of Directors, serving until the 2028 Annual Meeting.
• Proposals 2, 3, and 4 seek ratification and approval of revised compensation terms for Chief Executive Officer Miranda Toledano, Chief of Research & Development Gregory Burshtein, and Chief Financial Officer Dana Yaacov-Garbeli, respectively.
• Proposal 5 requests ratification and approval of the amended and restated compensation policy for the Company's directors and officers.
• Proposal 6 is an advisory, non-binding vote to ratify and approve the compensation paid to named executive officers, including compensation tables and narrative discussion.
• Proposal 7 concerns the ratification and approval of Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Limited (PwC), as the Company's independent auditors for the fiscal year ending December 31, 2025.
• The Board of Directors unanimously recommends a vote FOR each of Proposals 1 through 7.

Sentiment

Score: 7

Explanation: The document outlines routine corporate governance matters for an annual meeting, with the Board recommending approval of all proposals, indicating a generally positive and stable operational outlook from management's perspective.

Positives

• The Board of Directors recommends approval for all seven proposals, indicating internal alignment and confidence in the proposed actions.
• The election of Ms. Haya Taitel as a Class II director strengthens the Board's composition.
• Ratification of executive compensation terms and the overall compensation policy provides clarity and stability for management and governance.
• The appointment of Kesselman & Kesselman (PwC) as independent auditors ensures continued robust financial oversight for the 2025 fiscal year.

Management Comments

• "The Board of Directors recommends a vote FOR each of Proposals 1-7."

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Directly impacted by voting decisions on board composition, executive compensation, and auditor appointment, influencing corporate governance and potential future performance.
• Management/Executives: Their compensation terms are subject to shareholder approval, affecting their remuneration structure.
• Board of Directors: Will see a new Class II member elected and have their compensation policy ratified, impacting board dynamics and oversight.
• Auditors: Kesselman & Kesselman (PwC) will be appointed for the upcoming fiscal year, continuing their role in ensuring financial transparency.

Next Steps

• Shareholders are encouraged to access and review all important information contained in the proxy materials online.
• Shareholders can vote online, by telephone, by mail (if a card is requested), or in person at the Annual Meeting.
• The Annual Shareholder Meeting will be held on July 16, 2025, to vote on the presented proposals.

Key Dates

Keywords

Entera Bio, DEFA14A, Proxy Statement, Shareholder Meeting, Corporate Governance, Executive Compensation, Board of Directors, Auditor Appointment, Annual Meeting